1. Inicio
  2. Publicaciones
  3. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.

Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Cubillos-Zapata C
  • Campos-Rodríguez F
  • Sánchez de la Torre M
  • Nagore E
  • Martorell-Calatayud A
  • Hernández Blasco L
  • Chiner Vives E
  • Abad-Capa J
  • Montserrat JM
  • Cabriada-Nuño V
  • Cano-Pumarega I
  • Corral-Peñafiel J
  • Diaz-Cambriles T
  • Mediano O
  • Somoza-González M
  • Dalmau-Arias J
  • Almendros I
  • Farré R
  • López-Collazo E
  • Gozal D
  • García-Río F
  • Spanish Sleep Network

Grupos

Abstract

Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.

Datos de la publicación

ISSN/ISSNe:
0903-1936, 1399-3003

EUROPEAN RESPIRATORY JOURNAL  EUROPEAN RESPIRATORY SOC JOURNALS LTD

Tipo:
Article
Páginas:
-
PubMed:
30487198
Factor de Impacto:
3,398 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 20

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Proyectos y Estudios Clínicos

INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT11/037 . 2012

ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013

EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015

ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.

Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA

PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017

Cita

Compartir